Royal Bank of Canada assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report published on Friday morning, The Fly reports. The firm issued an outperform rating and a $23.00 price objective on the biopharmaceutical company's stock.
A number of other equities research analysts have also recently weighed in on the company. HC Wainwright restated a buy rating and issued a $27.00 price target on shares of Marinus Pharmaceuticals in a report on Friday, January 6th. StockNews.com upgraded Marinus Pharmaceuticals from a sell rating to a hold rating in a report on Monday, November 14th. Finally, Robert W. Baird lowered their target price on Marinus Pharmaceuticals from $32.00 to $24.00 and set an outperform rating on the stock in a report on Wednesday, November 9th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of Moderate Buy and a consensus price target of $28.13.
Get Marinus Pharmaceuticals alerts:Marinus Pharmaceuticals Stock Performance
MRNS opened at $5.65 on Friday. The stock has a market cap of $210.16 million, a P/E ratio of -12.28 and a beta of 1.10. The company has a debt-to-equity ratio of 0.91, a current ratio of 8.41 and a quick ratio of 8.40. The stock's 50 day simple moving average is $4.42 and its 200 day simple moving average is $5.46. Marinus Pharmaceuticals has a 1-year low of $3.46 and a 1-year high of $12.37.
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) last released its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of $0.25 by ($0.60). The firm had revenue of $2.34 million during the quarter, compared to analyst estimates of $28.56 million. Marinus Pharmaceuticals had a negative return on equity of 244.60% and a negative net margin of 77.96%. As a group, equities analysts anticipate that Marinus Pharmaceuticals will post -2.88 EPS for the current fiscal year.Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in shares of Marinus Pharmaceuticals by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,691,370 shares of the biopharmaceutical company's stock worth $11,248,000 after purchasing an additional 16,812 shares during the period. BlackRock Inc. lifted its stake in shares of Marinus Pharmaceuticals by 1.9% during the 3rd quarter. BlackRock Inc. now owns 959,198 shares of the biopharmaceutical company's stock worth $6,379,000 after purchasing an additional 17,887 shares during the period. Delphia USA Inc. purchased a new position in shares of Marinus Pharmaceuticals during the 3rd quarter worth $86,000. Renaissance Technologies LLC lifted its stake in shares of Marinus Pharmaceuticals by 23.2% during the 3rd quarter. Renaissance Technologies LLC now owns 193,325 shares of the biopharmaceutical company's stock worth $1,286,000 after purchasing an additional 36,425 shares during the period. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Marinus Pharmaceuticals by 392.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 527,925 shares of the biopharmaceutical company's stock worth $3,511,000 after purchasing an additional 420,802 shares during the period. Hedge funds and other institutional investors own 86.88% of the company's stock.
Marinus Pharmaceuticals Company Profile
(Get Rating)
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
See Also
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.